Table 1. Patient characteristics (N = 100 patients).
Characteristics | |
Age (yr), median (range) | 5.2 (1.4–16) |
1 y to less than 10 y | 80 |
at least 10 y | 20 |
Gender, No. | |
Male | 57 |
Female | 43 |
WBC count at diagnosis, No. | |
<10,000/µL | 61 |
10,000/µL–100,000/µL | 35 |
>100,000/µL | 3 |
>200,000/µL | 1 |
Risk group, No. | |
Standard-risk patients | 69 |
modified CCG-1881 | 2 |
modified CCG-1891 | 12 |
modified CCG-1952 | 55 |
High-risk patients | |
modified CCG-1882 | 31 |
FAB classification, No. | |
L1 | 75 |
L2 | 19 |
Not identified | 6 |
Immunophenotype, No. | |
Precursor B | 92 |
Precursor T | 6 |
Not available | 2 |
Cytogenetics, No. | |
t(12;21);TEL-AML1 | 17 |
t(9;22);BCR-ABL1 | 2 |
t(1;19);E2A-PBX1 | 1 |
p16 deletion | 2 |
hyperploidy | 12 |
hypoploidy | 4 |
Complex karyotype | 4 |
Normal karyotype | 44 |
Down syndrome (21 trisomy) | 2 |
Others | 7 |
Not available | 5 |
CNS involvement, No. | |
Absent | 89 |
Present | 5 |
Not available | 6 |
Day 7 BM response to treatment, No. | |
Leukemic blasts less than 25% | 73 |
Leukemic blasts at least 25% | 27 |
Event | |
Relapse | 12 |
BM | 4 |
CNS | 3 |
Testis | 2 |
BM+CMS | 2 |
BM+testis | 1 |
Death | 4 |
Secondary malignancy | 0 |
Grade 3,4 toxicity during treatment | |
Hyperbilirubinemia | 1 |
Liver enzyme dysfunction | 23 |
Febrile neutropenia without sepsis | 13 |
Sepsis | 15 |
Abbreviation: CCG, Children's Cancer Group.; BM, bone marrow; CNS, central nervous system.